Ampio Pharmaceuticals Inc.


Prices are adjusted according to historical splits.

Ampio Pharmaceuticals Inc. Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$7.69 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Ampio Pharmaceuticals Inc. had its IPO on under the ticker symbol AMPED.

The company operates in the Healthcare sector and Biotechnology industry. Ampio Pharmaceuticals Inc. has a staff strength of 9 employees.

Stock update

Shares of Ampio Pharmaceuticals Inc. opened at $0.26 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.26 - $0.29, and closed at $0.27.

This is a -0.48% slip from the previous day's closing price.

A total volume of 143,839 shares were traded at the close of the day’s session.

In the last one week, shares of Ampio Pharmaceuticals Inc. have slipped by -13.32%.

Ampio Pharmaceuticals Inc.'s Key Ratios

Ampio Pharmaceuticals Inc. has a market cap of $7.69 million, indicating a price to book ratio of 0.4707 and a price to sales ratio of 0.

In the last 12-months Ampio Pharmaceuticals Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-25781000. The EBITDA ratio measures Ampio Pharmaceuticals Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ampio Pharmaceuticals Inc.’s operating margin was 0% while its return on assets stood at -81.42% with a return of equity of -130.71%.

In Q3, Ampio Pharmaceuticals Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Ampio Pharmaceuticals Inc.’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ampio Pharmaceuticals Inc.’s profitability.

Ampio Pharmaceuticals Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.3776. Its price to sales ratio in the trailing 12-months stood at 0.

Ampio Pharmaceuticals Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$18.84 million
Total Liabilities
$3.92 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Ampio Pharmaceuticals Inc. ended 2024 with $18.84 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.84 million while shareholder equity stood at $13.85 million.

Ampio Pharmaceuticals Inc. ended 2024 with $0 in deferred long-term liabilities, $3.92 million in other current liabilities, 2000.00 in common stock, $-231719000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $16.95 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Ampio Pharmaceuticals Inc.’s total current assets stands at $18.32 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $218000.00 and inventory worth $0.00.

In 2024, Ampio Pharmaceuticals Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Ampio Pharmaceuticals Inc. paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Ampio Pharmaceuticals Inc. stock is currently trading at $0.27 per share. It touched a 52-week high of $9.705 and a 52-week low of $9.705. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.31 and 200-day moving average was $1.75 The short ratio stood at 1.13 indicating a short percent outstanding of 0%.

Around 750.6% of the company’s stock are held by insiders while 1317.6% are held by institutions.

Frequently Asked Questions About Ampio Pharmaceuticals Inc.

The stock symbol (also called stock or share ticker) of Ampio Pharmaceuticals Inc. is AMPED

The IPO of Ampio Pharmaceuticals Inc. took place on

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.


373 Inverness Parkway, Englewood, CO, United States, 80112